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The purpose of the immune system is to protect the body against infectious 
agents. When the immune system does not work correctly, it may cause various dis-
eases.  
Autoimmune diseases (ADs) are a wide range of related diseases in which the 
immune system produces an impaired response against its own cells, tissues and/or 
organs, causing inflammation and tissues damage. In most cases, the beginning of at-
tacks against the body’s self-molecules is unknown. There are more than 80 different 
autoimmune diseases, and they vary from common to very rare [1]. 
ADs can be divided into tissue-specific (such as Hashimoto’s thyroiditis, Type I 
or Immune Mediated Diabetes Mellitus), where unique tissue-specific antigens are tar-
geted, or systemic (for example Systemic Lupus Erythematosus, Rheumatoid Arthritis, 
Systemic Sclerosis ), in which multiple tissues are affected, and a variety of apparently 
ubiquitously expressed autoantigens are targeted [2].  
The development of AD depends on a combination of both genetic and environmental 
factors. The concordance rate of the disease is generally higher in monozygotic twins 
compared with dizygotic twins or at least compared to other family members, suggest-
ing a genetic contribution [3]. However, the concordance in identical twins is often in-
complete, and this indicates the presence of additional factors, presumably from the 
environment [4]. 
From the point of view of genetic predisposition, autoimmunity is associated with cer-
tain genes; some also are multigenic ADs, in which different genes contribute to the 
production of the abnormal phenotype [5]. Among the major candidates there are: 
human leukocyte antigen (HLA) allele (s) genes, T-cell receptor genes, cytokine and cy-
tokine receptor genes, immunoglobulin genes and immunoglobulin Fc receptor genes 
for various autoimmune diseases. 
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Some of these genes confer a high level of risk than others, for instance, the strongest 
allelic association was shown by the HLA genes, in many cases, they are considered as 
primary susceptibility factors for many autoimmune diseases [6]. 
From the standpoint of environmental exposure to chemicals, pharmacological prod-
ucts and pathogens there is a significant link with ADs in both human and animal mod-
els. [7] 
Some ADs may arise in response to pharmacological treatment. For example, drugs 
such as procaineamide and hydralazine can induce autoantibodies and lupus-like dis-
orders in patients [8]. Penicillamine has been associated with myasthenia gravis and a-
methyldopa is known to cause a form of hemolytic anemia. However, in some cases of 
AD’s drug-induced, ADs symptoms disappeared once the prescribed medication is dis-
continued [9]. 
Infections from certain viruses, bacteria, and mycoplasma can cause the onset of sys-
temic AD in genetically predisposed individuals. In addition, a bacterial or viral infec-
tion can trigger a severe increase in antibodies and autoreactive T cells, which may 
cause a worsening of existing symptoms. The viruses most involved in the onset of var-
ious ADs are: HSV-1, Coxsackie virus, EBV, HIV, HPV, or influenza virus [2]. Exposure to 
UV radiation, particularly UV-B rays, has been associated with the presence in flare-ups 
in lupus patients. In fact, in vitro studies suggest that exposure of DNA and snRNPs to 
UV-B cause autoreactive lymphocytes and their activation. The mechanism by which 
these environmental factors induce autoimmunity includes epigenetic changes (such 
as DNA methylation and histone modification), which can cause reaction with the self 
component to generate novel antigens, aberrant cell death releasing cellular material 
that can lead to inflammasome activation and production of pro-inflammatory cyto-
kines and molecular mimicry [10].  
Many ADs occur more frequently in women, but the reason has not yet been fully clari-
fied. Several studies suggest a role for female sex hormones [11], which can directly in-
teract with cells of the immune system through receptors, and influence by altering 
the production of antibodies and the proliferation of immune cells [9]. Reserchers have 
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suggested that women have a genetic predisposition to autoimmunity due to their se-
cond X chromosome [12,13]. Since one X chromosome is silenced by epigenetic mech-
anisms in women, it is possible that these epigenetic mechanisms contribute to the 
predisposition to autoimmunity through effects on the inactive X [14]. 
The ADs incidence appear to vary from country to country: this variation may be due 
to the uneven prevalence of an HLA allele linked to a particular AD (due to ethnic dif-
ferences) or of a triggering pathogen or chemical agent (due to geographic or envi-
ronmental differences) [2]. 
 
Systemic Lupus Erythematosus 
Introduction 
SLE is a systemic autoimmune disease with a broad spectrum of clinical presen-
tations and incompletely understood pathogenesis. This AD is characterized by altera-
tions in both the innate and adaptive immune system that lead to the loss of immu-
nologic tolerance and occurrence of auto-antibodies against nuclear material [15]. The 
term “lupus” from the Latin “wolf” has been widely used in the eighteenth century to 
describe a wide variety of skin lesions that was considered similar to that caused by 
the “wolf’s bite”. Biette et al produced one of the first descriptions of lupus in 1833. In 
1846 Ferdinand von Hebra introduced the butterfly term to describe the malar rash. 
Later in 1872 Kaposi et al founded  the systemic nature of the disease. The discovery of 
the LE phenomenon by Hargraves et al. in 1948 and Friou et al in 1958 provided the 
first bases on its pathogenesis [16].  
 
Epidemiology 
The incidence rates in North America, South America, and Europe range from 2 
to 8 cases per 100,000 per person-year. The SLE sex ratio is 6-10:1 (female:male) pri-
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marily affecting women in the fertile age. The prevalences of SLE vary considerably de-
pending on ethnicity [17]. In Caucasians is estimated a prevalence of around 20 
cases/100,000 per person-year and an incidence of 2-8 new cases per 100,000 person-
year. For North America’s black population these data should be tripled. The disease 
appears to be more common in urban than rural areas [18]. 
 
Natural course and aetiology  
SLE is a chronic disease with a variety of disease manifestations, and with et-
erogenity of presentations, which often delay diagnosis. Common manifestations in-
clude rashes, photosensitivity, arthritis, pleuritis, pericarditis, nephritis, neuropsychiat-
ric disorders, and hematological disorders. The disease course is characterized by peri-
ods of remission and exacerbation. 
SLE is characterized by autoantibody non-organ specific production (anti-nuclear anti-
bodies ANA, anti-dsDNA and anti-phospholipid antibody). The aetiology of SLE includes 




Genetic factors are implicated in pathogenesis with a concordance rate for lupus of 
24%–60% among monozygotic twins and 2%–5% among dizygotic twins or siblings 
[19]. The sibling recurrence risk ratio in SLE patients is 29-fold higher than in the gen-
eral population, and the higher concordance among monozygotic than dizygotic twins 
indicates the importance inheritance. [20] 
Genome-wide association studies (GWAS) have progressively improved the under-
standing of which genes are most critical to the potential for SLE: there are approxi-
mately 30 susceptibility loci for SLE. The most important genes associated are impli-
cated in immune response and inflammation (HLA-DR, PTPN22, STAT4, IRF5, BLK, 
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OX40L, FCGR2A, BANK1, SPP1, IRAK1, TNFAIP3, C2, C4, CIq, PXK), DNA repairs (TREX1), 
adherence of inflammatory cells to the endothelium (ITGAM), and tissue response to 
injury (KLK1, KLK3). [21] 
 
Epigenetic effects 
The risk for SLE may be influenced by epigenetic effects such as DNA methyla-
tion and post-translational modifications of histones (acetylation, deacetylation and 
methylation), which can be either inherited or environmentally modified. The regula-
tory regions of some genes known to be involved in the disease’s pathogenesis (for ex-
ample ITGAL, CD40LG, CD70, and PPP2CA) have been reported to be hypomethylated 
in SLE [22]. 
 
Environmental factors 
Epidemiological studies have identified a number of environmental factors sus-
pected of modulating susceptibility to SLE; some of these factors include viruses (such 
as EBV that has been identified as a possible factor in the development of lupus), hor-
mones, smoking, alcohol intake and exposure to ultraviolet light (the most obvious en-
vironmental factor that may exacerbate SLE sintoms), silica, organic solvents, including 
various drugs like hydralazine and INF-α. It is well established that certain drugs induce 
autoantibodies in a significant number of patients. Newer biologics and antiviral agents 
have been reported to cause drug-induced lupus (DIL) [23]. Socioeconomic factors 
have been associated with poorer outcomes and higher disease activity, [24] although 
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Hormonal factors 
The role of sex hormones (estrogens and androgens) in the development of SLE 
is suggested by the marked prevalence of females and from studies in animal models, 
where the addition of hormones can lead to autoimmune disease with an increase in 
auto-reactive B cells. In clinical practice, patients receiving oral contraceptives had 
flares; but a randomized controlled trial found out that combined oral contraceptives 
do not confer a higher risk of symptoms exacerbations of the disease in women with 
SLE clinically stable. [25]  
In postmenopausal women with SLE who have used hormone replacement therapy it 
was observed that there is a higher risk of getting mild to moderate lupus flares [26]. 
Pregnancy may aggravate SLE, in fact, the levels of estradiol and progesterone are 




Disease pathogenesis in SLE manifests itself as systemic acute and cronic in-
flammation that affects many organ systems. Furthermore, its onset can vary from pa-
tient to patient. 
In SLE there is an aberrant innate immune response that causes tissue injury by 
released infiammatory cytokines and by impaired activation of T and B cells. IFNand 
tumour necrosis factor (TNF), contribute to affected tissue injury and inflammation. 
These mediators, together with the cells producing them (macrophages, leucocytes, 
dendritic cells and lymphocytes), are the subject of investigation as potential thera-
peutic targets in lupus [28]. 
Most lupus patients have high titers of auto-reactive antibodies (such as dsDNA) asso-
ciated with their autoantigens and to complememt factor, which form circulating im-
mune complex (CICs). CIC deposition leads to infiammation [29]. Immune complexes 
and complement activation pathways are central players in tissue injury. In healthy in-
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dividuals, immune complexes are cleared by Fc and complement receptors, in patients 
with autoimmune disease they are not cleared because the Fc and complement recep-
tors are functionally deficient. Tissue damage is mediated by recruitment of inflamma-
tory cells, reactive oxygen intermediates, production of inflamatory cytokines, and 
modulation of the coagulation cascade [30]. The pathogenesis of SLE involves a multi-
tude of cells and molecules that participate in apoptosis, innate and adaptive immune 
responses. 
Briefly, we can summarize the abnormalities in the immune system in: 
 impaired clearance of immune complexes;  
 altered activity of networks idiotype-antidiotype that are unable to inactivate T 
and B lymphocytes;  
 Increased activity of T-helper to produce the antibodies by B-lymphocytes;  
 The suppressor T cells do not function properly; 
 alterations of the mechanisms of immunological tolerance. 
 
Classification criteria 
Consensus guidelines provided by the American College of Rheumatology (ACR) 
offer the basis for accurate and standardized diagnosis of SLE. The original recommen-
dations published in 1982 were updated in 1997 and contain 11 diagnostic categories 
(Table 1). The presence of any four of these criteria, either concurrently or consecu-
tively, confirms the diagnosis of SLE. The major change in the 1997 revision was the in-
clusion of newer immunological tests, namely, antiphospholipid (aPL) antibodies, anti-
cardiolipin (aCL) antibodies, and lupus anticoagulant (LAC), and the removal of redun-
dant histological preparations [31,32].  
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Table 1: ACR criteria 
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Activity indices 
The disease course is characterized by periods of remission, followed by pro-
gressive exacerbations, therefore it is important to categorize disease activity. Discern-
ing in an appropriate manner the disease activity is important for improving both 
prognosis and treatment. The indices validated and used are the following: the Euro-
pean Consensus Lupus Activity Measure (ECLAM), the British Isles Lupus Assessment 
Group Scale (BILAG), the National Institutes of Health SLE Index Score (SIS), the Sys-
temic Lupus Activity Measure (SLAM), and the SLE Disease Activity Index (SLEDAI). 
These indices have been developed in the context of long-term observational studies 
and have been shown to be strong predictors of damage and mortality, and reflect 
change in disease activity [18]. 
Bertsias et al [28] recommend the use of the ECLAM and the SLEDAI whom are more 
convenient for daily practice.  
 
Proteomic and SLE 
In SLE, the presence of specific serological markers is limited, and the patho-
genesis has not yet been fully elucidated. The diagnosis of SLE during the initial stages 
may be mistaken, this happens because the symptoms may be similar to those of other 
rheumatic diseases (such as RA and SSc); moreover, it requires a complex interpreta-
tion of the ACR criteria. 
The disease is also characterized by periods of remission and flare, and, being 
systemic, it could also manifests itself in different sites, and so far there are no specific 
tests to indicate accurately the picture. 
From the present literature [33-39], we note the importance of proteomics, 
which can help to find new therapeutic targets and it also could help to better under-
stand the cellular mechanisms. 
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Proteins are indeed important executors of physiological and cellular functions; 
changes in their expression reflect the different physiological conditions (e.g. healthy 
and sick). Observing the variations may help to better understand the pathogenesis in 
order to improve diagnosis and treatment. 
Plasma and Peripheral Blood Mononuclear Cells (PBMCs) can be obtained easily and 
non-invasively. Both the matrices are subjected to rapid changes in response to differ-
ent signals, such as during inflammatory states. Plasma is one of the most widely used 
blood component, while in recent years we have seen a greater interest in PBMCs.  
PBMCs are mainly composed of monocytes and lymphocytes, these cells are the most 
involved in the immune response. Observing the changes in their proteome may help 
us to have a deeper knowledge of their function in various diseases [40-42]. 
 
Cytokines and SLE 
Cytokines are molecules produced by various types of cells and secreted into 
the surrounding medium, usually in response to a stimulus. The development of an ef-
fective immune response involves lymphoid, inflammatory and hematopoietic cells 
[43].  
The term cytokine includes a large and diverse family of polypeptide regulators widely 
produced throughout the body by cells of different embryonic origin.  
Cytokines are essential for the development and operation of both innate and adaptive 
immune response, even though not limited to the immune system. A large variety of 
cells is able to secrete cytokines, but the two main sources of these mediators are T 
helper and macrophages. 
The general characteristics of the cytokines may be briefly summarized as follows:  
 proteins with molecular weight comprised between 10 and 50 kD;  
 cytokines act on their target cells via specific receptors, usually equipped with 
high or very high binding affinity; 
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 the actions of cytokines can be divided into "autocrine" (when the target cell of 
a specific cytokine is represented by the same cell that produces it), "paracrine" 
(when the target cell is located in the proximity of the cell responsible for the 
production) or more rarely "endocrine" (if the target cell is located remote 
from the cell responsible for the cytokine secretion and reaches the target via 
the bloodstream);  
 cytokines can direct their action towards many different cell types. This feature 
is known with the term pleiotropism. Pleiotropism means also that a cytokine 
can perform different actions on the same cell line; 
 One of the features of cytokines is the redundancy of the actions of these 
molecules, in fact many of these soluble molecules share the same actions, 
sometimes even against the same cell type [43]. 
These mediators are involved in the pathogenesis of autoimmune diseases, including 
SLE and RA. In SLE, several of these cytokines are overexpressed and contribute to the 
pathogenesis, in the activity or organ involvement of the disease.  
The most involved cytokines are those produced by the interaction of different T cell 
subsets. For example Th1 (IL-1, IL-6, IFN-, TNF-) and Th17 (IL-17, IL-21,IL-22) cyto-
kines subset generally drive pathogenic effector responses while. Th2 (IL-4, IL-5, IL-13) 
and Treg (TGF- and IL-10) cytokines mediate regulatory response (44). 
Even chemokines (chemoattractan cytokines) that exert their effects by attracting in-
flammatory cells, including monocytes, neutrophils and T lymphocytes, to sites of in-
flammation, are implicated in the pathogenesis of SLE, and in some studies, the ex-
pression was found to be increased and correlated with renal involvement and disese 
activity [45,46]. 
The measurement of cytokines in SLE can be useful in order to monitor the dis-
ease more accurately. In fact, it may be useful for identifying flare, assistance in moni-
toring response to therapy, provide information regarding the organs involvement and 
identification of possible therapeutic targets. Indeed, some therapies that inhibit their 
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action have been successfully used for the treatment of other rheumatic autoimmune 
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In ADs, particularly in SLE, early diagnosis, flare or remission phases can be dif-
ficult to identify, because of complex etiopathogenesis, heterogeneous presentation of 
symptoms, and unpredictable course. In addition, the initial symptoms may include 
signs or symptoms common among different ADs. 
The definition of specific serological markers is essential for early differential 
diagnosis. There are no set of biomarkers that can be used reliably to confirm the 
presence of SLE or to monitor its progression with specificity and sensitivity.  
Starting from these assumptions, the aim of this study was to observe the 
changes in the proteome and in cytokines expression of SLE patients, in order to in-
crease our knowledge about pathogenesis and to find possible diagnostic markers 
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Twenty one SLE patients, (20F:1M, 48,2±6,14 years), twelve RA patients (12F, 
64,15±12,17 years, used as pathological control) and twenty one healthy volunteers 
(20F:1M, 42,14±9.58 years) were enrolled in the study. 
All subjects  were recruited from the Cit.Il.AKeA Project (This project was sup-
ported by Regione Autonoma della Sardegna, Legge regionale 7/2007, “Le interleuchi-
ne nella longevità, nelle patologie sistemiche e neoplastiche: semplici marcatori o fat-
tori predittivi per la risposta terapeutica?” Cit. Il.AKeA [49], P.I. Luca Deiana, approved 
by the local bioethics) in collaboration with the unit of Medical Pathology A.O.U. Uni-
versity of Sassari and all signed a written consent prior to blood sampling. 
SLE diagnosis is based on the 1987 American College of Rheumatology criteria 
[50]. Each SLE patient had the same disease activity, calculated with SLEDAI (Score ≤6, 
inactive disease). All partecipants were Caucasians people. Blood samples were col-
lected into vacutainers containing potassium EDTA as anticoagulant (Vacutest Kima). 
For 2D analyses we have used pooled samples for each group; while for ELISA and 
Western Blot validations we used single samples.  
All SLE patients were on treatment using standard protocol incorporating glu-
cocorticoids and immunosuppressive agents while healthy subjects didn’t suffered 
from any autoimmune disease. 
 
Plasma samples  
 
The red cell fraction was separated from plasma by centrifugation at 2500 g at 
4°C for 15 min and the clear plasma supernatant was stored in aliquots frozen at -80°C 
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until use. For cytokines analysis plasma samples were centrifuged again at 10000g for 
10min at 4°C to remove completely platelets and precipitates. 
 
Removal of the high-abundance proteins from plasma samples 
For each group (SLE, RA and Healthy), were created plasma pools.  
For protein extraction we used the ProteoMiner™ ProteinEnrichment Kits (Biorad). The 
The Proteominer is a new tool used to reduce the concentration of proteins in complex 
biological samples. The presence of high-abundance proteins in biological samples 
(such as albumin and immunoglobulins) makes the detection of medium and low 
abundance proteins very difficult. The technology is based on the interaction of the 
samples with hexapeptides related to chromatographic supports (Figure 1). The high-
abundance proteins are washed during procedures, while the low-abundance proteins 
are focused on their specific ligands. 
In the first step was removed the storage buffer from columns by washing them with 
600 l of wash buffer (30-60 sec) twice after this process the column conteined 100 l 
of settled beads, ready for sample binding. 
The plasma samples were centrifuged at 10000g for 10 min to clarify.  
One ml of sample was added to each column. The columns were positioned on a rota-
tional shaker for 2 hr at room temperature. Then, the columns were washed for 3 
times with 600 l of wash buffer. After, all the buffer was removed, 600 μl of deionized 
water was added and the columns have been rotatedend-to-end for 1 min. The mate-
rial was discarded. Then 100 l of rehydrated elution reagent was added and the col-
umns were incubated at room temperature and lightly vortex several times over a pe-
riod of 15 min. In the next step the eluate was placed in a clean collection tube and 
centrifuged at 1000g for 30–60 sec. The eluate contains the proteins at medium and low 
abundance ; this step was repeated two more times.  
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Figure 1: High-abundance proteins saturate their ligands (yellow and red beads) and excess protein is 
washed out during the procedure. Low-abundance proteins are concentrated on their specific ligands 




PBMCs were isolated using a Ficoll-Paque Plus density gradient (Amersham 
Pharmacia Biotech) according to the manufacturer’s instructions. 
The cells were resuspended in phosphate-buffered saline (PBS). Soluble proteins were 
extracted from PBMCs by incubation on ice in 200 μl of lysis buffer (7M urea, 2M 
thiourea, 4% CHAPS, DNasi (3μl/ml), RNasi (3μl/ml)and Complete Protease Inhibitor 
Cocktail(5μl/ml) for 10 min. Were carried 2 freeze-thaw cycles at -80°C for 5 min. Sam-
ples were centrifuged at 14000g for 30 min at 4°C and supernatant containing proteins 
recovered. For proteomics analyses the protein extract of PBMCs was pooled for each 
group (SLE,RA and Healthy). The pool is prepared by mixing defined units of protein ex-
tract (50 µg of protein) belonging to the same group. 
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Protein quantification 
The concentration of plasma and PBMCs proteins were determined using the 
RC/DC Protein Assay (BioRad) according to the manufacturer’s instructions. 
The RC/DC Protein Assay uses a Lowry method modified to reduce agent com-
patible (RC) as well as detergent compatible (DC). The assay based on the reaction of 
proteins with an alkaline copper tartrate solution and Folin reagent where the color 
development is primarily due to the aminoacids tyrosine and tryptophan, and to a 
lesser extent, cystine and histidine. Proteins reduce the Folin reagent by loss of 1, 2 or 
3 oxygen atoms, thus producing one or more of several possible reduced species which 
have a characteristic blue colour with a maximum absorbance at 750 nm. A standard 
curve was constructed using albumin as standard sample in a range between 0.2 and 
2mg/ml.  
 
Two dimensional SDS PAGE 
 
Total protein extracts of plasma and PBMCs samples were separated by 2D-
PAGE gels. Analytical gels contained 150 μg of total protein extracts; for preparative 
gels 1000 μg of protein were applied. Three experimental replicates were performed 
for each sample pool belonging to the three different groups. 
Isoelectrofocusing (IEF) 
Plasma: The first dimension (Isoelectric Focusing, IEF) was performed on IPG 
(Immobilized pH gradient) strips linear pH 3-10, 17 cm from BioRad. At first, the strips 
were rehydrated for 20 hours at 20°C without voltage in rehydration buffer (Urea 8M, 
Tiourea 2M, 4% CHAPS, Destreak reagent, 10mM DTT, 1% carrier ampholyte pH 3-10 
and 0.05% bromophenol blue) and covered with mineral oil. The proteins were sepa-
rated using the Protean IEF Cell system (Biorad) according to the following protocol: 2 
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hr at 250 V, 2 hr at 500 V, 2 hr at 750 V, 2 hr at 1000 V, 2 hr at 5000 V, 2 hr at 8000 V, 
at 8000 V for 50.000 Volthours, for a total of 80.000 V). Focused IPG strips were equili-
brated in two steps (15 min each) in 1 ml freshly prepared sample buffer (50 mM Tris–
HCl pH 8.8, 6 M urea, 20% (v/v) glycerol and 2% (w/v) SDS, 1% (w/v) bromophenol 
blue) supplemented with 2% dithiothreitol and 2.5% iodoacetamide respectively [51]. 
PBMCs: IEF was performed on IPG strips linear pH 4-7, 17 cm from BioRad. At 
first, the strips were rehydrated for 21 hours in rehydration buffer (Urea 8M, Tiourea 
2M, 4% CHAPS, Destreak reagent, 10mM DTT, 1% carrier ampholyte 4-6 and 0.05% 
bromophenol blue) and covered with mineral oil. The proteins were separated in the 
first dimension according to the following protocol: 2 hr at 250 V, 2 hr at 500 V, 2 hr at 
750 V, 2 hr at 1000 V, 2hr at 5000 V,  2 hr at 8000 V and at 8000 V for 50.000 Volthours 
for a total of 80.000 Vh. After isoelectric focusing the IPG strips were equilibrated in 
the same protocol of plasma. 
 
SDS-PAGE 
To separate the protein in the second dimension we performed a size denatur-
ing sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS PAGE). Equilibrated 
IPG strips were embedded into 0.5% agarose on top of SDS polyacrylamide gels. The 
anionic detergent sodium dodecyl sulfate (SDS) denatures the proteins and provides 
the protein with a negative net charge. 
For the second dimension 13,5% (for plasma proteins) and 12,5% (for PBMCs 
proteins) SDS-polyacrylamide gels were used. The gels were made using the Multicast-
ing Chamber from BioRad; using this apparatus we were able to produce ten gels si-
multaneously with a high reproducibility. The gels were run on a Protean Multicell 
(BioRad) were six gels at a time can be run. The instrument is connected to a cooling 
bath to avoid excessive heating of the buffer. The lower chamber was filled with buffer 
containing Tris 0.125M, Glycine 0.96M, SDS 1%, while the upper chamber had the 
same composition but with the SDS concentration doubled (2%). This modification was 
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suggested by the work of Weirner et al [52] who proved that in order to minimize gel 
smearing the concentration of SDS in the cathodic buffer needs to be increased.  
After completion of the run, analytical gels were stained in SYPRO® Ruby Pro-
tein Gel Stain whereas preparative gels in Coomassie staining solution. SYPRO Ruby 
stain is ready to-use and is a ultrasensitive, luminescent stain for the detection of pro-
teins separated by polyacrylamide gel electrophoresis.  
After electrophoresis, the gel was placed in a clean container with 100 ml of fix 
solution (50% methanol, 7% acetic acid) and put in an orbital shaker for 30 minutes. 
After that, we added the SYPRO® Ruby stain and incubated in an orbital shaker over-
night. The day after, the gels were transferred to a clean container and washed in 100 
ml of wash solution (10% methanol, 7% acetic acid) for 30 minutes. The transfer phase 
helps to minimize background-staining irregularities and stain speckles spot on the gel. 
Before imaging the gels were rinse in ultrapure water. The gels were scanned using 
Chemidoc™ XRS (BioRad).  
Coomassie staining is cheap, quantitative and reproducible. The staining solu-
tion used was composed of 0.05% coomassie Blue R-250 dissolved in 50% methanol, 
10% acetic acid and H2OmilliQ. 
Gels were then washed with H2OmillQ and destained in destaining solution 
containing the same components of the staining solution except for the dye. Gels were 
scanned using a GS-800 densitometer (BioRad). 
 
Image analysis  
Images were analysed using the PDQuest Advance 2D Analysis Software (Bio-
Rad). We performed the image analysis following the steps summarized below: 
 Scanning: gels are turned into pixel data and then each map is turned into a se-
ries of pixels describe by their optical density value (OD). 
 Filtering: this step eliminates noise, background effect. 
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 Automated spot detection: identification of spots present in each gel in-
dipendently, then spots are located on the gel image fitted by ideal gaussian 
distributions and quantified by the sum of the OD values within each gaussian 
distribution. 
 Matching of protein profiles: 2D gels are then edited and matched to one an-
other in a “match set”, to achieve this, landmarks are used, consisting of refer-
ence spots used by PDQuest to align and position the match set members for 
matching. 
 Normalization: is used to compensate gel to gel variations due to sample 
preparation and loading, staining and destaining procedures. 
 Spots were first detected and matched automatically to a master gel selected 
by the software and then we corrected manually the errors in the editing end 
matching steps. 
 Spot volumes were normalised with the option “Local Regression Model” 
method (LOESS); this method uses the raw quantity of each spot in a member 
gel, multiplied by a factor based on the local regression method of the matched 
spots. In order to exclude artifacts and false positive we manually confirmed 
both matching and data quality of all the spots: only those spots that were de-
tectable in all gels of a sample set were considered for evaluation. The quantity 
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For western blot analysis were analysed the same protein extracts used for 2D 
PAGE. 
The samples were boiled in laemli buffer (TrisHCl 1M pH6.8, glicerol, 10% SDS, 
0.5% bromophenol blue) for 4 minutes at 95°C and then loaded on a 12.5% acrylamide 
gel. After SDS PAGE the gel was transferred to a nitrocellulose membrane using the 
Trans Blot Plus Cell system from BioRad. The gel size was measured and two whatman 
filter papers and one nitrocellulose membrane of the same size were prepared. The fil-
ter papers and nitrocellulose were soaked in transfer buffer (25mM Trizma base, 
200mM glycine in H2O milliQ). Then the soaked nitrocellulose and the polyacrylamide 
gel were placed on to one of the filter papers and covered with the second filter paper. 
This stack was placed between two sponge cloths before they were placed into the 
holding device of the blot chamber. 
Then, blotting was performed at 60V for 1 hour. During the blotting procedure 
the instrument was connected to a cooling bath to avoid excessive heating of the 
buffer. 
After disassembling, the membrane was soaked in blocking buffer containing 
3% albumin in PBS-T (PBS 10X, 20% (v/v) methanol and 0.05% (v/v) Tween-20 in 
ddH2O) for 1 hour at room temperature. It was then shortly rinsed with washing buffer 
(PBS-T) and the primary antibody (mouse monoclonal antibody peroxiredoxin2, dilu-
tion 1:3000, Pierce) was applied in the same buffer overnight at 4°C. The blots were 
washed 3 times for 10 min in washing buffer before the secondary horseadish peroxi-
dase labelled goat anti-mouse antibody was applied in the same buffer at a dilution of 
1:2000 for 80 minutes at RT. The membranes were washed five times in PBS-T before 
the blots were developed using the ECL Immunoblotting Detection Kit from Amer-
sham. The images were acquired with the Chemidoc ™ XRS from BioRad. The exposure 
time was set at 60 sec and then the image analyzed for densitometric studies. 
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Mass spectrometry and protein identification  
 
Mass spectrometry is the most common, high throughput method for identify-
ing proteins from 2D gels. It accurately weights peptides after digestion with a suitable 
enzyme and the masses of these peptides can then be matched against the theoretical 
peptide masses of known proteins for identification. 
In the present work, protein spots with a statistically significant variation 
(p≤0.05, ANOVA), showing an over two-folds difference in volume, were selected as 
differentially expressed and analyzed by MS and MS/MS analyses. MS analyses were 
performed on a MALDI-TOF mass spectrometer micro MX™(Waters). 
The main parameters used were: reflectron mode, positive polarity, mass range 
800-4000 Da. Mass spectra were calculated using an external calibration, with the fol-
lowing mixture of peptides: Bradykinin fragment 1-7 (m/z 757.3997),Angiotensin II 
(m/z 1046.5423 ), P14R synthetic peptide (m/z 1533.8582), ACTH fragment 18-39 (m/ z 
2465.1989), Insulin oxidized B chain (bovine) (m/z 3494.6513) (ProteoMass™ Peptide 
& Protein MALDI-MS Calibration KIT, SIGMA). One μl of tryptic peptide solution of each 
digested spot was mixed with an equal amount of the matrix α-cyano-4-
hydroxycinnamic acid (CHCA), prepared in 0,2% Trifluoroacetic acid (TFA) and in 70%  
Acetonitrile (ACN), applied on a MALDI plate and dried at room temperature. All spec-
tra were analyzed using the Mass Linx v 4.1 software (Waters). Protein identification 
was performed by peptide mass fingerprinting (PMF) using MASCOT software search-
ing at www.matrixscience.com. Search parameters were restricted to Homo sapiens 
taxonomy using the NCBInr database. Enzyme selection was trypsin, with up to one 
missed cleavage permitted. Carbamidomethylation of cysteines was selected as a fixed 
modification; Gln -> pyro-Glu (N-term Q), Oxidation (M) as variable modifications. Pro-
tein mass was unrestricted and peptide mass tolerance typically set at ±150 ppm. Mass 
values were entered as monoisotopic MH+.  
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To get a further confirmation of the proteins identified, some of them, considered 
most relevant, were subjected again to identification through LC-MS/MS analyses. LC-
MS/MS analyses was performed on an HPLC-Chip/Ion Trap (Agilent). All searches were 
performed using the Proteome Discoverer version 1.4 with the following parameters: 
Mascot search engine, database SwissProt , the taxonomy Homo sapiens, a maximum 
of 2 sites of hydrolysis  missed, enzyme trypsin, oxidation of methionine and cycliza-




A non competitive ELISA kit (Cloud-Clone Corp. Assembled by Usnc Life Science 
Inc. Huston, USA) for human clusterin was used following manufacturer instructions 




Plasma concentration of the cytokines was determined by the Bio-Plex MAGPIX 
Multireader (Biorad) instrument. 
The Bio-Plex system is based on xMAP technology developed and owned by 
Luminex Corp, which can theoretically support up to 50 different ELISA assays for a 
single sample. Each test is performed on the surface of a polystyrene bead, diameter 
of 5.6 m. Each bead contains inside two fluofores in different ratio, which allow the 
beads’ classification in 100 different regions (Figure 2). Each set of beads can be conju-
gated with a different antibody. 
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The principle of the Bio-Plex Pro™ Assay (Bio-Rad) is similar to the ELISA-
sandwich. The beads (50 l) associated with the specific antibody are incubated with 
the sample (diluted 1:4 with Bio-Plex sample diluent) in a microplate. After one hour of 
incubation in the dark and agitation, 3 washes with wash buffer are performed, and 
the biotinylated secondary antibody (25 l) is added. The biotinylated secondary anti-
body binds to another epitope of the molecule. 
After 30’ of incubation in the dark and stirring, the streptavidin-phycoerythrin 
(SA-PE) (50l) is added for 10’. The phycoerythrin acts as a fluorescence detector 
(Figure 3). 
After incubation, the plate is inserted into the player's Bio-Plex MAGPIX; the 
reader employs light-emitting diodes (LEDs) and a charge-coupled device (CCD) imager 
to illulinate and image a monolayer of immobilized magnetic beads. Precision fluidics 
align the beads in a single line from a stream that leads into a cell where two LED ex-
cite the beads individually. The red led (635 nm) excites the dye in each ball, identify-
ing the specific beads. The green led (532 nm) excites phycoerythrin reporter that gen-
erates a signal that is read by a photomultiplier tube which allows to quantify the ana-
lyte captured (figure 4). The processor manages high-speed digital data and the Bio-
Plex Manager software presents the data as mean fluorescence intensity (MFI) and as 
a concentration (pg/ml). Concentration of the analyte bound to each bead is propor-
tional to the MFI of the reporter signal.  
 
Figure 2: different bead set 
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Figure 3: Bio-Plex sandwich immunoassay 
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All the statistical analyses were performed using STATA Release 9 and SPSS v 17 
softwares. To compare changes of the mean intensity values of protein spots between 
healthy, SLE and RA groups a parametric test, the One Way ANOVA, was performed 
followed by “Fisher’s least significant difference method” (LSD); p-values ≤0.05 were 
considered significant. 
Among all statistically significant spots, only those that showed changes of the 
mean intensity values at least by a factor 2 compared to the healthy group were se-
lected, in order to exclude the impact of experimental variability and consider more re-
liable data.  
To compare the different cytokine expression patterns among the three groups, 
the Kruskall Wallis test and the Dunn’ methods  were permormed for pair compari-
sons, because the data did not follow a normal distribution.  
To compare the changes in plasma clusterin concentration and in optical den-
sity of Peroxiredoxin 2 among the three groups the ANOVA test was performed. Re-
ceiver operating characteristic (ROC) curve was used to assess the diagnostic value of 
statistically significant cytokines. 
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Materials 
IPG strips pH 4-7 17cm and pH3-7 17cm, Bio-Plex Pro™ Assay were purchased 
from BioRad Laboratories (CA, USA), Ampholyte 4-6, Ampholyte 3-10, Dithiothreitol 
(DTT), urea and thiourea, DNasi, RNasi ProteoMass™ Peptide & Protein MALDI-MS 
Calibration KIT from Sigma-Aldrich (MO, USA), COmplete Protease Inhibitor Cocktail 
Tablets from Roche (), Mouse Monoclonal antibody Anti-Peroxiredoxin 2 from PIERCE 
Thermo Fisher Scientific Inc. (IL, USA) and Goat anti-mouse Secondary antibody SC-
2005 from Santa Cruz Biotechnology (CA, USA), Magic Mark XP western protein stan-
dard from Invitrogen (CA, USA), ELISA Kit for Clusterin (CLU) Human from Cloud-Clone 
Corp. Assembled by Usnc Life Science Inc. (TX, USA). All other reagents were of the 
highest quality available. 
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In order to know the pattern of protein expression on matrices of plasma and 
PBMCs in SLE patients a proteomic approach has been used including 2D-PAGE and 
mass spectrometry analyses.  
 
2D electrophoresis maps  
The proteomic comparisons were based on the differences of mean intensity 
values of protein spots between SLE patients, RA patients and healthy subjects. For 
each “matchset” (3 replicates for each group) we had the same SSP (standard spot 
number) assigned by the software. The software used for image analysis (PD QUEST 
advanced) has detected about 500 and 600 valid spots in PBMCs and plasma samples 
respectively. Among these 13 spots and 8 spots were found to show significant chang-
es (higher than two folds, p ≤ 0.05, ANOVA test) in intensities compared with the 
healthy group in PBMCs and plasma samples respectively. 
The figures 5 and 6 show the 2D PBMCs and plasma maps obtained in our labo-
ratory through the method described in materials and methods. The images were 
found to be similar either between gels or between groups (Figures 7 and 8). 
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Figure 5: Typical gel image obtained in our lab for PBMCs proteins in 12.5 % gel 
 
Figure 6: Typical gel image obtained in our lab for Plasma proteins after removal of high-abundance pro-
teins in 13.5 % gel 
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Proteins identification by Mass Spectrometry 
 
Differentially expressed protein spots were excised from the gels, digested with 
trypsin and the proteolytic fragments analyzed by MALDI-TOF mass spectrometry as 
described in materials and methods section. 
 
 
Figure 7: Matchset example created by PDQuest software for PBMCs pool sample 
Figure 8: Matchset example created by PDQuest software for Plasma pool sample 
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PBMCs proteins identification 
We found 13 protein spots that undergoing statistically significant changes in 
mean intensity values between the three groups considered (Figure 9) : six spots 
showed OD values higher in SLE patients than in healthy subjects; five different spots 
increased in intensity in RA patients compared to healthy subjects.  
One spot underwent similar changes in intensity both in SLE patients and in RA 
patients compared with healthy controls: Finally, one spot was missing only in SLE pa-
tients. (Table 2).  
 
Figure 9: Differentially expressed protein spots on PBMCs gel 
 
We observed that in SLE patients and in pathological controls the protein patterns that 
undergo changes compared to healthy subjects are different . 
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The data that we consider most interesting were the absence of the spot pro-
tein T-complex protein 1 subunit beta only in SLE patients and the overexpression of 
peroxiredoxin 2 (fold regulation of approximately 17 times) in SLE patients than in 
healthy subjects (Figure 10). 
Table 2 
Mass spectrometric identification of spots using the Mascot search engine. In the table are reported 
SSP number, NCBInr accession number, protein name, their fold regulation values (ratio), molecular 
weight (MW) in daltons (Da), isoelectric point (pI), sequence coverage (C%) and matching peptides 
(QM). 
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Figure 10: Zoom on the position of T-complex 1 protein spot (below in the figure) and Peroxiredoxin 2 
(above in the figure).  
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Plasma proteins identification  
Of the eight differentially expressed spots, four increased in intensity values 
both in SLE patients and in RA patients compared with healthy subjects (Figure 11).  
 
 
Figure 11: Differentially expressed protein spots on plasma gel 
 
These proteins have been identified as Crystal Structure Of Lipid-Free Human 
Apolipoprotein A-I (two spots), apolipoprotein J precursor or clusterin, aptoglobin or 
HP protein, ficolin-2 isoform, Crystal Structure Of Fibrinogen Fragment D. One spot, 
identified as apolipoprotein E is overexpressed in RA patients compared with healthy 
controls; another spot identified as Chain B, Crystal Structure Of Fibrinogen Fragment 
D is up-regulated in SLE patients with respect to healthy subjects (Table 3).  
Chapter 4: Results 
 
Sara Pinna 
Proteomic analysis of human plasma and Peripheral Blood Mononuclear Cells in 
Systemic Lupus Erythematosus patients 




Mass spectrometric identification of spots using the Mascot search engine. In the table are reported SSP 
number, NCBInr accession number, protein name, their fold regulation values (ratio), molecular weight 
(MW) in daltons (Da), isoelectric point (pI), sequence coverage (C%) and matching peptides (QM). 
 
Among the identified proteins, we decided to carry out further analyses only on 
clusterin, because it is the only protein that shows a significant increase in the mean 
intensity values in SLE patients compared both in healthy that pathological controls 
(Figure 12).  
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Figure 12: Zoom on the position of clusterin in Plasma gel (ssp 3407) 
 
In Table 4 and 5 are reported the protein spots whose identifications were con-
firmed also with LC-MS/MS analyses 
Table 4 
 
Mass spectrometric identification of spots using the Mascot search engine. In the table are reported SSP 
number, SWISS Prot accession number, protein name, molecular weight (MW) in Kilo daltons (KDa), cal-
culated isoelectric point (Calc pI), sequence coverage (C%), and ion score. 
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Mass spectrometric identification of spots using the Mascot search engine. In the table are reported SSP 
number, SWISS Prot accession number, protein name, molecular weight (MW) in Kilo daltons (KDa), cal-
culated isoelectric point (Calc pI), sequence coverage (C%), and ion score. 
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Western blot analysis 
 
To validate the proteomic analysis data, western blot analysis for Peroxiredoxin 
2 were performed. The Figure 13 shows the bands detected by this antibody on a 1-D 
gel when 50 µg of total protein extracts were loaded per well. 
Our data showed that expression of the Peroxiredoxin 2 (PRDX2)  protein was 
significantly increased in the SLE PBMCs (2.4 folds) compared to healthy subjects (Fig-
ure 14, p-value= 0.025). This finding was consistent with the proteomic analysis data.  
 
 
Figure 13: One-dimensional western blot analysis. PRDX2 and GAPDH immunodetection to assess PRDX2 
up-expression in SLE patients. 
 
Figura 14: Bar charts reporting PRDX 2 relative abundance in Healthy, SLE and RA subjects. Following da-
ta normalization, PRDX 2 was confirmed as differentially expressed in SLE patients compared to healthy 
controls (p= 0.025) and also for RA patients vs healthy controls (p = 0.05).  
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We wanted to quantify with a reliable technique the clusterin concentration in 
our plasma samples, using an available commercial kit for human clusterin.  
We found significative differences between the SLE groups versus RA patients. 
The table below shows the ANOVA result. 
 
Table 6: Comparison of clusterin levels among enrolled individuals. 
 
* SLE vs RA ** SLE vs Healthy *** RA vs Healthy 
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Table 7 shows the cytokines analysed, and figures 15-17 show the box plots for 
each analyte.  
Cytokine levels that were not detectable were considered to be zero. To inves-
tigated the reproducibility of cytokine levels in patients with SLE, RA and healthy con-
trols we used a two-tailed Kruskal–Wallis test. The p-values less than 0.05 were con-
sidered to be statistically significant. Table 8 reports the cytokines statistically signifi-
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Figure 15: Levels of plasma Th17 cytokines in the different groups. Cytokines are expressed as pg/ml. 
The median levels in the three groups (SLE, RA, Healthy) were respectively: IL-1 2.26, 1.53, 1.29; IL-4 
0.12, 0.12, 0.12; IL-6 1.4, 11.46, 0.2; IL-10 1.38, 9.94, 1.38; IL-17A 26.64, 20.40, 35.87; IL-22 6.34, 10, 
6.34; IL-25 0.45, 1.38, 0.45; IL-33 26.56, 35.17, 26.56; IFN- 76.40, 62.87 34.93; TNF-0.72, 4.97, 0.72; 
sCD40L 50.37, 27.93, 22.88; *p-value<0,05, **p-value<0,001. 
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Figure 16: Levels of plasma chemokines in the different groups. Cytokines are expressed as pg/ml. The 
median levels in the three groups (SLE, RA, Healthy) were respectively: IL-8 7.32, 8.73, 5.95; MCP-1 
66.67, 72.46, 27.39; MIP-1 1.78, 1.37, 1.62; MIP-183.78, 63.72, 46.38; IP-10 621.38, 476.36, 363.34. 
*p-value<0,05, **p-value<0,001.  
 
Figure 17: Levels of others cytokines in the different groups. Cytokines are expressed as pg/ml. The me-
dian levels in the three groups (SLE, RA, Healthy) were respectively: IL-1ra 645.91, 223.150, 150.95; IL-5 
3.75, 2.49, 1.98, IL-7 16.47,8.55, 7.35; IL-12(p70) 29.44, 13.51, 12.19; VEGF 0.62, 20.785, 0.62.*p-
value<0,05. 
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Receiver Operating Characteristic (ROC) curve 
In order to validate the diagnostic discriminating power of cytokines we per-
formed further statistical analyses using the Receiver Operating Characteristic (ROC) 
curve. 
This technique include sensitivity, specificity, positive predictive power, nega-
tive predictive power and accuracy. ROC analysis quantifies the accuracy of diagnostic 
tests or other evaluation modalities used to discriminate between two states or condi-
tions, which are here referred to as healthy and SLE disease. The discriminatory accu-
racy of a diagnostic test is measured by its ability to correctly classify known normal 
and abnormal subjects.  
ROC curve shows the characteristics of a diagnostic test by graphing the false-
positive rate (1-specificity) on the x-axis and the true-positive rate (sensitivity) on the 
y-axis for various cutoff values. Each point on the ROC curve represents a sensitivi-
ty/specificity pair corresponding to a particular decision threshold. A test with perfect 
discrimination (no overlap in the two distributions) has a ROC curve that passes 
through the upper left corner (100% sensitivity, 100% specificity).  
Accuracy is measured by the area under the ROC curve (AUC). An area of 1 (perfect di-
agnostic ability) represents a perfect test; an area of 0.5 (no diagnostic ability) repre-
sents a worthless test. A rough guide for classifying the accuracy of a diagnostic test is 
the traditional academic point system: 
 AUC=0.5 test is not informative  
 0.5<AUC≤0.7 inaccurate test 
 0.7<AUC≤0.9 moderately accurate test 
 0.9 <AUC≤1 highly accurate test 
 AUC=1.0 perfect test 
Usually it is considered appropriate to use a diagnostic test with an area under the 
curve ≥ 0.8 (Figure 18). 
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ROC curves were constructed for all the cytokines that have undergone statistically 
significant changes of the concentration values among the 3 groups (Figure 19). 
 
 
Figure 18: Example of ROC Curve;  for A the AUC is 1, for B the AUC is 0,8 and for C the AUC is 0,5 
 
 
Figure 19: The ROC curves graph for nine cytokines. The AUC values are: IL-1=0.761, IL-1ra=0.764, IL-
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The analyses revealed that the area under curves (AUC) of MCP-1, MIP-1b and 




Figure 20:  Test set ROC curves for SLE patients vs Healthy subjects for the panel of MCP-1, MIP-1b and 
sCD40L. Sensitivity=(TP/P), Specificity=(1-TN/(FP+TN)) PPR= Positive Predictive Rate (TP/TP+FN); FPR= 
Negative Predictive Rate (FP/FP+TN); TP=true positive; FP=false positive; TN=true negative; FN=false 
negative 
 
Correlation between drugs dosage and clusterin level. 
The effects of different drug treatments on the expression of the clusterin and 
the cytokines (with p-values ≤ 0.05) were analyzed by Spearman’s rank correlation 
where drug doses were available, by dividing the patients into subgroups based on the 
presence or absence of a certain drug treatment and comparing the means of analysed 
parameters between the two groups (Tables 9-12). 
Using these approaches, we found no evidence for any effect of different drug 
treatments on the analysed parameters. 
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In this study, first of all, a proteomic approach has been used to identify the 
pattern of protein expression on matrices of plasma and PBMCs in SLE patients. The 
proteomic comparisons were based on the differences of mean intensity values of pro-
tein spots among SLE patients, RA patients and healthy subjects. We decided to use 
patients with rheumatoid arthritis (another systemic autoimmune disorder) as patho-
logical control, because the first SLE symptoms can be misdiagnosed; therefore, having 
a similar control can be useful to exclude alterations in common between the two syn-
dromes. 
In PBMCs, 6 proteins were upregulated (Protein disulfide-isomerase A3, Glu-
tathione S-transferase , Peroxiredoxin-2, Transaldolase and pyruvate kinase), one was 
down regulated (Cytochrome b-c1 complex subunit 1) and another protein was missing 
(T-complex protein 1 beta subunit) in SLE patients compared to healthy subjects (Table 
2). 
Proteins that have undergone major changes in their expressions, especially in 
SLE patients, can be grouped into three functional categories: cell stress (T-complex 
protein 1 beta subunit, Protein disulfide-isomerase A3), redox-regulation (Cytochrome 
b-c1 complex subunit 1, Glutathione S-transferase p and Peroxiredoxin-2) and energy 
metabolism (Transaldolase and pyruvate kinase m2). 
In the group of proteins associated with oxidative stress a remarkable change 
was found. Among them, we confirmed increased expression of PRDX2 with western 
blot analysis. 
Glutathione S-transferases (GSTs) are a family of Phase II detoxification en-
zymes that work to protect cellular macromolecules from attack by reactive electro-
philes. Specifically, GSTs catalyse the conjugation of glutathione (GSH) to a wide vari-
ety of endogenous and exogenous electrophilic compounds. Glutathione conjugation is 
the first step in the mercapturic acid pathway that leads to the elimination of toxic 
compounds. [53] 
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While the ligand-binding function remains unclear, sequestering molecules may 
serve a regulatory role, preventing cytotoxic ligands from interacting with their targets. 
Recent studies have demonstrated a regulatory role for the p and m classes of GSTs in 
the mitogen-activated protein (MAP) kinase pathway that participate in cellular sur-
vival and death signalling. Specifically, Glutathione S-transferases isoform p (GST) was 
shown to be an endogenous inhibitor of c-Jun N-terminal kinase 1 (JNK1), a kinase in-
volved in stress response, apoptosis, and cellular proliferation [54,55]. 
In chronic lymphocytic leukemia patients, GST levels were elevated in individu-
als responding to chlorambucil and corticosteroids, and this expression was further 
enhanced in patients who had received multiple rounds of therapy and whose disease 
was classified as resistant to chlorambucil/steroid treatment [56]. Y Dai et al.[36] 
showed that GSTp expression in SLE patients was downregulated. 
The protein disulfide isomerase A3 (PDIA3), also known as Erp57, acts as a 
chaperone into the endoplasmatic reticulum (ER). The expression level of PDIA3 in-
creases in response to cellular stress due to its function. [57,58]. Lately a study, 
showed that PDIA3 had an antiapoptotic effect in the melanoma cell line A375 after ER 
stress was induced [59]. PDIA3 probably plays a role in the malignant transformation of 
prostate and cervical cancer [60,61]. The expression of this gene is induced during 
neoplastic transformation, possibly leading to redox-dependent modulation of cancer-
relevant regulatory factors [62,63]. In pterygium the increase in PDIA3 protein expres-
sion is most likely due to elevated cellular stress [64]. In addition, PDIA3 has recently 
gained attention due to its function as a component of the peptide-loading complex of 
the major histocompatibility complex (MHC) class I pathway [65]. In PDIA3-deficient 
mice, this complex is impaired and negatively influences presentation of antigenic pep-
tides [66].  
Cytochrome b-c1 complex subunit 1 is a component of the ubiquinol-
cytochrome c reductase complex (complex III or cytochrome b-c1 complex), which is 
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part of the mitochondrial respiratory chain. This protein may mediate formation of the 
complex between cytochromes c and c1. 
Transaldolase 1 (TALDO 1) is a key enzyme of the nonoxidative pentose phos-
phate pathway providing ribose-5-phosphate for nucleic acid synthesis and NADPH for 
lipid biosynthesis. This pathway can also maintain glutathione at a reduced state and 
thus protect sulfhydryl groups and cellular integrity from oxygen radicals. 
Recently, it was proved that TALDO 1 is involved in different autoimmune diseases (MS 
and RA) and other malignancies. In MS patients, recombinant TALDO1 stimulates the 
aggregate formation and proliferation of T lymphocytes [67,68]. Peptides of TALDO1 
bind to MHC of T cells and induce cytotoxic T cell response in MS patients [69]. 
In colorectal cancer, by proteomic approaches, Ma et al showed that TALDO 1 was 
overexpressed. [70]. Previous studies showed that TALDO-deficient mice exhibited ox-
idative stress and mitochondrial dysfunction in hepatocytes [71].  
The pyruvate kinase M2 isoform (PKM2) is an enzyme that catalyses the tran-
sphosphorylation from phosphoenolpyruvate to ADP as the last step of glycolysis to 
generate ATP.  
PKM2 is a ubiquitous prototype enzyme present in all tissues during the embryonic 
stage and it is gradually replaced by other isozymic forms in specific tissues during de-
velopment. PKM2 is also involved in many other nonglycolytic functions; in fact, PKM2 
interacts with a variety of biological molecules, such as molecules involved in intracel-
lular membrane trafficking, signaling and transcription factors and it is also known to 
interact with pathogenic proteins [72]. In a recent report, PKM2 is found to be highly 
immunomodulatory by interacting with SOCS3 (suppressor of cytokines signaling 3) 
and during interaction with APC (depending upon CD28 receptor on surface) [73,74]. 
PKM2 is shown to interact with IgE receptor on the cells, resulting in the inhibition of 
its activity [75]. 
T-complex protein 1 is a molecular chaperone; assists the folding of proteins 
upon ATP hydrolysis. As part of the BBS/CCT complex, it may plays a role in the assem-
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bly of BBSome, a complex involved in ciliogenesis regulating transports vesicles to the 
cilia. T-complex protein 1 plays a role, in vitro, in the folding of actin and tubulin [76]. 
In our study, we found that the expression of the beta subunit of T-complex protein 1, 
was abolished in SLE patients. Interestingly, mutations of this protein have been shown 
to be associated with cytoskeletal disorganization and increased sensitivity to micro-
tubule destabilizing agents. 
The peroxiredoxin 2 (PRDX2) is a cytoplasmic enzyme that reduces intracellular 
reactive oxygen species (ROS) levels. In cardiomyocytes, PRDX2 overexpression pro-
tects from peroxide-induced apoptosis and necrosis, while downregulation of this en-
zyme promotes injurious effects of oxidative stress [77]. The antiapoptotic role of this 
enzyme has been established in red blood cells as well as in pancreatic cells [78,79].  
In our study, the intracellular levels of PRDX2 protein in PBMCs were greatly increased 
in SLE patients compared with healthy subjects (2.4 folds). This fact suggests the possi-
bility that PRDX2 may be elevated as part of the inflammatory response in SLE PBMCs 
[80]. PRDX2 is a redox enzyme with extensive roles in immune regulation: Moon et al 
showed [81] that in mice, PRDX2 inhibits immune cell responses by scavenging ROS, 
and Yang et al [82] showed that intracellular PRDX2 is a negative regulator of the pro-
inflammatory toll-like receptor 4 (TLR4) signaling pathway. PRDX2 is also involved in 
the pathway of T cell receptor signaling by consuming H2O2 [83]. Moreover, PRDX2 is 
an inhibitor of apoptosis [84]. It is unclear whether the observed increase in the intra-
cellular PRDX2 content of the PBMCs from SLE patients plays a protective or pathologi-
cal role. It is probable that in SLE, PRDX2 and its regulation of ROS are critical in con-
trolling T cell responses.  
In plasma samples, protein expression patterns of SLE patients and the patho-
logical controls with RA were similar; in fact, of the eight differentially expressed spots 
between patients and controls, four spots increased in intensity both in SLE and in RA 
patients. These proteins belong to the Apolipoprotein AI/A4/E, Clusterin, Peptidase S1, 
Ficolin 2, Fibrinogen alpha/beta families. The only proteins differentially expressed be-
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tween SLE and RA patients that change compared to healthy subjects are Clusterin (SLE 
vs Healthy) and Apolipoprotein E (RA vs Healthy). 
Our results show that in SLE patients five protein spots are differentially expressed: 
Apolipoprotein A1, Haptoglobin, Fibrinogen, Ficolin 2 and Clusterin (Table 3). Among 
all, Clusterin expression was validated by ELISA. 
Apolipoprotein A1 (APO A1) is a protein that, in humans, is encoded by the 
APOA1 gene. Apo A1 is a major constituent of the high-density lipoprotein (HDL) com-
plex and has a specific role in lipid metabolism; furthermore, apo A1 has anti-
inflammatory properties both in acute and chronic inflammation . This protein pro-
motes cholesterol efflux from tissues to the liver for excretion and it is a cofactor of 
lecithin cholesterol-acyltransferase (LCAT) which is responsible for the formation of 
most plasma cholesteryl esters [85]. In some autoimmune diseases, apo A-I is consid-
ered to be an immune regulator and can suppress pro-inflammatory cytokines gener-
ated by activated T cell [86]. Malle et al [87] demonstrated an enhanced intracellular 
biosynthesis and secretion of apolipoproteins SAA and A-I in HUH-7 cells in response to 
the agonists IL-1, IL-6, butyrate and dexamethasone, alone or in combination. García-
Gómez et al [88] found that a low dose of glucocorticoids, in RA patients, was associat-
ed with an increase in HDL-c and HDL2-c levels, without significantly affecting other 
lipoprotein fractions; in fact, no change was detected in the major protein constituent 
of HDL, APO A-I. 
Some researchers believe that serum apoA-I concentrations should be declined during 
active phase of autoimmune diseasesand this protein has played an important role in 
anti-inflammation, such as RA and SLE [89-91]. Our results, contrary to the hypothesis 
of above mentioned studies, showed an increase in plasma levels of the protein in RA 
and SLE patients rather than in healthy subjects. This difference could be due to the 
fact that all tested patients showed an inactive phase of the disease. 
Haptoglobin (Hp) is a positive member of the acute phase proteins (APPs) and it 
is mainly synthesized in the liver; the protein is responsible for transporting hemoglo-
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bin. Its synthesis is induced by IL-6, IL-1β and TNF and exerts antioxidant properties. It 
also plays an important role in maintaining homeostasis and in the damaged tissues 
repair mechanisms. Hp also has anti-inflammatory effects in autoimmune diseases 
[92]. The HP22 genotype was shown to be over-represented in inflammatory diseases 
such as RA, SLE, primary sclerosing cholangitis (PSC) and diabetes mellitus type 2 
(T2D)[93,94]. In general, serum levels of Hp increase during inflammatory processes 
[95] or glucocorticoids admnistration [96]. 
Plasma fibrinogen is an important component of the coagulation cascade, as 
well as a major determinant of blood viscosity and blood flow. Fibrinogen has a bio-
logical half-life of about 100 h and it is synthesized predominantly in the liver. As a 
clotting factor, fibrinogen is an essential component of the blood coagulation system, 
being the precursor of fibrin. Plasma fibrinogen is an acute-phase protein, and it is 
therefore likely to increase with inflammation or tissue necrosis. Interpretation of 
raised fibrinogen may be complicated by its behavior as an acute phase reactant [97]. 
Impaired fibrinolysis has been reported in patients with SLE and may contribute to 
both the development of hypercoagulability and an increased risk of thrombosis [98]. 
In their study, Spengler et al [99] showed an increase of immunoglobulin and plasma 
fibrinogen, which induced red blood cells of SLE patients to agggregate at higher rate, 
with aggregates greater size rather than healthy subjects. Epidemiological studies sug-
gest that elevated plasma fibrinogen levels are associated with an increased risk of 
cardiovascular disorders, such as stroke, ischemic heart disease and other throm-
boembolism [100-101]. 
Ficolin-2 or L-Ficolin is a serum molecule, structurally and functionally related 
to collectins. It is able to opsonize infecting microorganisms and to activate the lectin 
pathway of complement in cooperation with mannan-binding lectin (MBL)-associated 
serine proteases (MASPs) . Recently, Ficolin -2 has been the subject of several disease 
association studies, providing evidence that ficolin-2 complements MBL is an impor-
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tant component of innate immunity in the circulation. In healthy subjects the distribu-
tion of serum ficolin 2 is perfectly Gaussian [102]. 
Conversely, Watanabe et al [103] observed that serum levels of L-ficolin in patients 
with SLE were significantly lower when compared with those in healthy subjects. Our 
results are in agreement with Østergaard et al [104] because they showed  an increase 
in plasma levels of ficolin-2 in SLE patients compared to healthy subjects. 
In a recent study [105], the serum levels of Ficolin-2 were found to be significantly 
higher in RA patients than in healthy subjects, which is also consistent with our results. 
Clusterin (CLU) is a glycoprotein with a nearly ubiquitous tissue distribution that 
has been reported to be implicated in several physiological processes such as lipid 
transportation, complement inhibition, tissue remodelling, membrane recycling, cell-
cell interaction and promotion or inhibition of apoptosis. 
CLU may have a protective role against disease activity in SLE, since disturbances in 
apoptosis and complement function play an important part in the pathogenesis of SLE 
[106,107]. Newkirk MM et al [108] showed an inverse correlation between plasma 
and/or serum CLU and the activity of disease. In our study, we found an increase of 
Clusterin plasma levels in SLE patients compared with healthy subject, and this might 
be related to the fact that the patients were in a stable phase of the disease. 
 
As a second aim of this study, we compared the expression pattern of cytokines 
of SLE and RA patients with healthy subject. Numerous studies suggest the importance 
of monitoring plasma levels of cytokines in patients with various autoimmune diseases 
and point out, in particular, the crucial role of cytokines in the pathogenesis of SLE. 
All the cytokines described in literature are molecules potentially involved in 
the pathogenesis of SLE. Cytokines are soluble factors that act as mediators for the dif-
ferentiation, maturation and activation of the various immune cells. Altered levels of 
cytokines in the plasma would be a major cause of an immune dysregulation followed 
by local inflammatory processes and tissue damage. Observing the plasma cytochines 
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variations, may help us to understand SLE mechanisms as well as to find new ideas for 
designing biomarkers and therapeutic agents. 
We decided to observe changes in the expression of cytokines produced by 
Th1, Th2 and Th17, and some chemokines. This analysis showed that some cytokine 
plasma concentrations (Table 8) were significantly higher in SLE patients than in 
healthy subjects (IL-1 1.29, 2.26 pg/ml, IFN-34.93, 76.40 pg/ml, IP-10 363.34, 621.38 
pg/ml, IL-1ra 150.95, 645.91 pg/ml, IL-5 1.98, 3.75 pg/ml, IL-7 7.35, 16.47 pg/ml, MCP-
1 27.39, 66.67 pg/ml, MIP-146.38, 83.78 pg/ml, sCD40L 22.88, 50.37 pg/ml; in 
Healthy and SLE respectively). 
In order to validate any diagnostic power of the cytokines, we have carried out 
the ROC curves analyses. Our results suggests that the combination of MCP1, MIP-1 
and sCD40L cytokines might be used as potential biomarkers (AUC=0.973).  
The higher plasma levels of cytokines and chemokines that we found in SLE pa-
tients are in agreement with some reports [109,110]. For example, Eriksson et al. [109] 
found higher plasma levels of MIP-1β, MCP-1, and higher serum levels of RANTES in 
SLE patients when compared with healthy individuals. In contrast, Kaneko et al. [111] 
did not find differences in serum concentrations of MIP-1β between SLE patients and 
healthy subjects. Narumi et al [112] showed that serum levels of IP 10 increased in SLE 
patients and are strongly correlated with the disease activity. Another study showed 
that plasma concentrations of IP10 and MCP-1 were increased in SLE patients. They 
also showed a strong positive correlation between IP-10 levels and SLE disease activity 
and suggested a possible correlation between SLE renal involvement and IP-10 [113]. 
In some studies it has been observed an increase in the serum concentration of IFN, 
and that its serum levels are correlated with the disease activity [114,115]. 
The major functions of IL-1, is to act as mediators of the host inflammatory 
reaction to infections (116). The principle source of IL-1 is the activated macrophage. 
At higher concentrations, IL-1 exerts endocrine effects, inducing fever and acute-phase 
proteins. Of the IL-1 family members, IL-1R antagonist (IL-1Ra) have been the most 
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studied in autoimmune diseases. Cigni et al (117) also showed IL-1 serum levels higher 
in SLE group than in the control group  
sCD40L is considered a proinflammatory and prothrombotic cytokine in cardio-
vascular diseases [118,119]. The major sources of the soluble form of sCD40L are acti-
vated CD4 lymphocytes [120] and activated platelets [121]. Increased levels of sCD40L 
have been found in SLE [118,122], RA [123], and systemic sclerosis [124]. Increased 
levels of sCD40L have been correlated with the disease activity in SLE [120] and many 
studies have documented the effectiveness of anti-CD40L therapy in lupus nephritis at 
many murine models [125,126]. 
IL-7 is a 25-kd glycoprotein and was first isolated based on its inductive effect to 
differentiate immature B cell that depends on IL-7 in the program of its development 
[127]. This cytokine is mainly secreted by stroma cells in primary lymphoid tissues and 
organs including bone marrow and thymus [128,129]. The proliferation of T cell con-
taining autoreactive T cell is regulated by IL-7, which may probably be related with the 
increase of self-antigen [130]. Ben-David et al. have found that IL-7 is over-expressed 
in SLE afflicted mice [131]. Furthermore, a recent study has also revealed that SLE pa-
tients have a high level of sIL-7R in sera, which is associated with SLE disease activity 
index scores, and the serological level of sIL-7R is reduced after immunosuppressive 
therapy, a main and effective treatment for SLE currently [132].  
IL 5 is a cytokine that acts as a growth and differentiation factor for both B cells 
and eosinophils. The increased production of this cytokine may be related to patho-
genesis of eosinophil-dependent inflammatory diseases. In one study unusual IL-5 
overproduction resulted in SLE patients with eosinophilia [133]. 
Several studies showed that IL-6 and TNF-plasma levels are higher in SLE patients. In 
our study the plasma levels of these cytokines were as low as in healthy subjects; the 
lower levels of secreted TNF-andIL-6 observed in our SLE patients, might be ex-
plained partly by the medication that our patients received. In fact, 
glucocorticosteroids can affect the expression of several cytokines [134,135]. This in-
Chapter 5: Discussion 
Sara Pinna 
Proteomic analysis of human plasma and Peripheral Blood Mononuclear Cells in 
Systemic Lupus Erythematosus patients 
International PhD School in Biomolecular and Biotechnological Sciences-University of Sassari 
63 
formation is important for an appreciation of our results, since all patients were receiv-
ing low doses of prednisone. Brink et al. reported that even low doses of steroids can 
inhibit cytokine synthesis in patients with SLE [136]. In another study, Swaak et al. ob-
served that patients with SLE taking prednisone at a dose of 15 mg/day showed a re-
duction in ‘‘ex-vivo’’ production of IL-6 and TNF-[137]. 
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In summary, a comparative proteomic study was performed to analyse the dif-
ferential protein expression in the human PBMCs and plasma of SLE patients and 
healthy subjects. 
We have identified the significant protein spots using MALDI-TOF and LC-
MS/MS analyses, and confirmed by Western blotting and ELISA analyses. 
Several proteins were differentially expressed in the PBMCs from SLE patients. 
Among these, PRDX2 may be used as candidate biomarker or target protein for further 
investigations. In plasma, we showed that plasma clusterin levels increased, but this 
increase is not statistically significant. 
These proteomic results provide suggestions for understanding the molecular 
mechanisms of SLE, as well as the physiological changes correlated with SLE disease. 
From cytokines analyses, we attributed to MCP-1, MIP-1 and sCD40L a hypo-
thetical role as biomarkers with diagnostic performance optimized with two different 
statistical methods. These results suggest the potential usefulness of these cytokines in 
SLE as potential biomarkers, able to discriminate with a significant diagnostic perform-
ance. 
Further studies are required to confirm the results presented. SLE patients 
should be expanded in order to have the possibility to analyse data both from treated 
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